LegalView Reports Details of a New Traumatic Brain Injury Treatment Approved by FDA

Share Article

LegalView informed traumatic brain injury (TBI) patients of a new treatment approved by the FDA that is being studied and may offer TBI victims an improved outcome after being injured. The treatment uses a device known as the ThermoSuit System, which induces rapid cooling in a brain injured victim.

LegalView, the most comprehensive legal resource available on the Internet, informed traumatic brain injury information blog readers of a new treatment that may help improve a brain-injured victim's recovery. The treatment uses the ThermoSuit System, which includes a method that induces rapid cooling among patients. The system is currently used for victims of cardiac arrest and heart attacks, however, researchers at the University of Texas Health and Science Center and the National Institute of Neurological Disorders and Stroke (NINDS) have found that using the hypothermic method on traumatic brain injury (TBI) patients for several hours may improve their long-term recovery. The U.S. Food and Drug Administration (FDA) also recently approved the rapid cooling device for treatment in clinical trials of TBI patients.

Nearly 5.3 million Americans currently suffer from TBI and many of the TBI symptoms can be long lasting, severely affecting a victim's life. Some of the symptoms can include memory loss/amnesia, delayed thinking, mood changes, sensory disorders, sleep disruption, etc. To learn more about finding assistance if dealing with TBI or to learn about developing a potential Brain Injury lawsuit, contact a TBI law firm that can provide information on litigation, which may result in monetary compensation for damages incurred.

LegalView also offers hundreds of other information portals on legal topics ranging from the most recent Byetta risks, to patients trying to overcome a truck accident injury, to individuals suffering from Cipro side effects.

In August, the FDA released information that it would be increasing the Byetta drug labeling after several reports found that the drug may have been causing life-threatening pancreas problems among patients. Byetta is a type 2 diabetes drug that has allegedly been linked to hemorrhagic pancreatitis and necrotizing pancreatitis among patients and may even be responsible for the deaths of two patients. Those who are currently taking the drug should contact their physician to better understand the Byetta side effects and may want to seek legal counsel to protect themselves as well.

Individuals who may have recently been involved with a truck accident should consider seeking legal counsel, as truck accidents have been estimated as the most costly and fatal accidents of all vehicular accidents. To better understand the details of a truck accident contact an experienced truck accident lawyer.

Cipro is an antibiotic belonging to the fluoroquinolone drug family. The FDA recently increased the fluoroquinolone family of drugs to a black-box labeling, which is the harshest labeling that a drug can receive. Cipro (ciprofloxain) along with Levaquin, Factive, Avelox, Cipro XR, Proquin XR, Noroxin and Floxin, all have been linked to tendon ruptures and tendonitis among patients. The severe side effects have been associated with patients taking the antibiotics both short- and long-term. Patients who are suffering from the severe side effects should contact an experienced pharmaceutical lawyer to learn about becoming involved in a potential Cipro class action lawsuit.

About LegalView: is a public service brought to you by Legal WebTV Network, LLC, a Limited Liability Corporation created by a group of the nation's most highly respected law firms: Anapol Schwartz; Brent Coon and Associates; Burg Simpson; Cohen, Placitella and Roth; James F. Humphreys and Associates; Lopez McHugh; and Thornton and Naumes. For more information on the accomplishments and track records of's superior sponsoring law firms and to get in touch with LegalView attorneys, visit LegalView at


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Katie Kelley

Alan Haburchak
Visit website